Efficacy evaluation of pharmaceutical optimized ramipril 1.25mg [F-4] with essential hypertension

ABSTRACT

Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. ACE inhibitors or angiotensin converting enzyme inhibitors reduce peripheral vascular resistance via blockage of the angiotensin converting enzyme. This action reduces the myocardial oxygen consumption. This study aimed to evaluate the efficacy of once-daily optimized Ramipril 1.25 mg [F-4] versus placebo. Placebo-controlled, comparative study. This study was conducted in the department of Biochemistry, University of Karachi from January 2010 to June 2010. This was multicenter, randomized, placebo-controlled, comparative study. Patients were selected from different hospitals of Orangi Town Karachi and study was conducted in the department of Biochemistry, University of Karachi. Patients were randomized to receive optimized Ramipril 1.25 mg [F-4] once daily and Placebo once daily for 8 weeks. The efficacy variable was change from baseline at the end of study which was evaluated. The patients treated with optimized Ramipril 1.25 mg tablet [F-4] alone, blood pressure reduction was lower, although significant; reaching values of 139.9 +/- 11.3 / 89.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. The results of this study demonstrated that the optimized Ramipril 1.25 mg [F-4] has a high antihypertensive efficacy and achieve desired blood pressure for eight weeks